Last reviewed · How we verify
CSL425
CSL425 is a recombinant human monoclonal antibody that targets and neutralizes respiratory syncytial virus (RSV) to prevent infection.
CSL425 is a recombinant human monoclonal antibody that targets and neutralizes respiratory syncytial virus (RSV) to prevent infection. Used for Prevention of respiratory syncytial virus (RSV) disease in infants and young children.
At a glance
| Generic name | CSL425 |
|---|---|
| Sponsor | Seqirus |
| Drug class | Monoclonal antibody (RSV neutralizing antibody) |
| Target | RSV fusion (F) protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
CSL425 binds to the fusion (F) protein on the surface of RSV, blocking the virus's ability to enter and infect host cells. By providing passive immunization through direct viral neutralization, the antibody aims to prevent RSV disease in vulnerable populations. This approach offers immediate protection without requiring the host immune system to generate its own antibody response.
Approved indications
- Prevention of respiratory syncytial virus (RSV) disease in infants and young children
Common side effects
- Injection site reactions
- Fever
- Upper respiratory tract infection
Key clinical trials
- A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults (PHASE2)
- A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children (PHASE2)
- A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA (PHASE2)
- A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |